About
The independently assessed, expert-led Research Grant Initiative Find For Rare aims to improve patient care and management by promoting and recognising research in three lysosomal storage disorders – Fabry disease, alpha-mannosidosis, and cystinosis
The Research Grant Initiative
Find For Rare research grants are designed to support original research projects that aim to advance knowledge in the field of:
Fabry disease
Alpha-mannosidosis
Cystinosis
This includes projects that aim to further our understanding of the rare diseases and how to manage them. For more details on the types of projects eligible for funding, check out the grant scope and application criteria.
Researchers are eligible to apply for grants up to €50,000 to support their project.
All submitted research proposals will be evaluated by the Steering Committee, an independent scientific board of leading experts in the field of lysosomal storage disorders.
Call for applications is now closed!
All applications must be submitted to the Grant Office by the application deadline, 31 December 2024.
See more information on the timelines.Downloads
Download the brochure for a comprehensive overview of the Find For Rare Research Grant Initiative
Brochure
Apply for grant
Chiesi
Chiesi Group at a glance
With over 85 years of experience, Chiesi is an international biopharmaceutical group with local community roots, certified B Corp.
We are a Benefit Corporation, a family-owned business with a long heritage in discovering and developing medical solutions to satisfy unmet needs and support patients and their carers through their entire health journey.
The Chiesi Group counts
6,500+ employees.
Chiesi operates in 31 countries and its solutions are present in 100 nations.
The Chiesi Group has 7 R&D centres: Italy, France, the US, Canada, China, the UK, and Sweden. 687+ researchers with 39 programmes. 21,4% of revenues are invested in R&D.
Action areas:
Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is one of Chiesi Group’s business units that was established to deliver innovative therapies and solutions for people living with rare diseases. As a family business, Chiesi Group acts by vocation as a force for good, for society, and the planet.
Therefore, it strives to create a world able to guarantee all people equal access to therapy for any disease, with the opportunity for people to live the most fulfilling life possible.
The unit collaborates with the rare disease community around the globe to bring a voice to underserved people in the healthcare system.
At Chiesi, we are making a rare difference.
We are passionate
about what we do and compassionate towards individuals with rare diseases, their caregivers, and partners
We listen to and understand
the needs of the community that we are privileged to serve, and we aspire to provide it with support throughout its journey
We are committed
to removing obstacles to provide people living with rare diseases with the tools they need. With equal energy, we contribute to the societal imperatives of overcoming disparities and ensuring health for people of all ages
Our rare disease areas of focus:
Inborn errors of metabolism, Ophthalmology, Endo-metabolic diseases, Dermatology, Haematology, and Immunology.
Steering Committee
The Steering Committee is an independent scientific board of 10 leading experts in the lysosomal storage disorders field specialised in Fabry disease, alpha-mannosidosis, and cystinosis.
Steering Committee members:
- Alessandro Burlina, Bassano del Grappa, Italy
- Camilla Tøndel, Bergen, Norway
- Christina Lampe, Giessen, Germany
- Christoph Wanner, Würzburg, Germany
- Dieter Haffner, Hannover, Germany
- Elena Levtchenko, Amsterdam, Netherlands
- Francesco Emma, Rome, Italy
- Joao Goncalves, Lisbon, Portugal
- Karolina Stepien, Manchester, United Kingdom
- Nicole Muschol, Hamburg, Germany
Steering Committee members will review and evaluate the research proposals, meet to discuss the shortlisted proposals, and select the research grant recipients.
Steering Committee members will not evaluate research proposal applications in cases where this is a conflict of interest.
Chiesi will not in any way influence the application, evaluation, nor grant selection process.
